According to the latest research analysis,the global market for Lung Disease Therapeutics should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By country, China accounted for percent of the global market last year and China’s market share increased from percent to percent. China Lung Disease Therapeutics market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029. The United States Lung Disease Therapeutics market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By segment, Hospital Pharmacies grew percent to account for percent of the total market sales, and Retail Pharmacies grew percent.
This report studies and analyses global Lung Disease Therapeutics status and future trends, to help determine the Lung Disease Therapeutics market size of the total market opportunity by Disease Type, by Distribution Channel, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Lung Disease Therapeutics, and provides market size (US$ million) and Year-over-Year growth, considering 2022 as the base year.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
To assess the competitive environment within the market including supplier revenue, market share, and company profiles.
Highlights
(1) Global Lung Disease Therapeutics market size, history data 2018-2023, and forecast data 2024-2029, (US$ million)
(2) Global Lung Disease Therapeutics by company, revenue, market share and industry ranking 2018-2023, (US$ million)
(3) China Lung Disease Therapeutics by company, revenue, market share and industry ranking 2018-2023, (US$ million)
(4) Global Lung Disease Therapeutics key consuming regions, consumption value and demand structure
(5) Lung Disease Therapeutics industry chains, upstream, midstream and downstream
Understanding Market Segments by Key Players: Insights and Opportunities
GSK
AstraZeneca
Boehringer Ingelheim
Novartis
Mylan
Vertex Pharmaceuticals
F. Hoffman La Roche
Teva Pharmaceuticals
Cipla
Fibrogen
Liminal Biosciences
PharmAkea Therapeutics
IQVIA
Market segment by Disease Type, covers
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Lung Cancer
Other Lung Diseases
Market segment by Distribution Channel, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Breaking Down Market Segments by Region: A Deep Dive Analysis
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Uncovering Market Potential: What Our Report Includes
Chapter 1: to describe Lung Disease Therapeutics product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Lung Disease Therapeutics market share and ranking of major manufacturers, revenue, 2018-2023
Chapter 3: China Lung Disease Therapeutics market share and ranking of major manufacturers, revenue, 2018-2023
Chapter 4: Lung Disease Therapeutics industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Disease Type, consumption value, percent & CAGR, 2018-2029
Chapter 6: Segment by Distribution Channel, consumption value, percent & CAGR, 2018-2029
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2018-2029
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2018-2029
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions
1 Market Overview
1.1 Lung Disease Therapeutics Definition
1.2 Global Lung Disease Therapeutics Market Size and Forecast
1.3 China Lung Disease Therapeutics Market Size and Forecast
1.4 China Percentage in Global Market
1.5 Lung Disease Therapeutics Market Size: China VS Global Growth Rate, 2018-2029
1.6 Lung Disease Therapeutics Market Dynamics
1.6.1 Lung Disease Therapeutics Market Drivers
1.6.2 Lung Disease Therapeutics Market Restraints
1.6.3 Lung Disease Therapeutics Industry Trends
1.6.4 Lung Disease Therapeutics Industry Policy
2 Global Leading Players and Market Share
2.1 By Revenue of Lung Disease Therapeutics, Global Market Share by Company, 2018-2023
2.2 Global Lung Disease Therapeutics Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Lung Disease Therapeutics Concentration Ratio
2.4 Global Lung Disease Therapeutics Mergers & Acquisitions, Expansion Plans
2.5 Global Lung Disease Therapeutics Major Companies Product Type
2.6 Head Office and Lung Disease Therapeutics Production Site of Key Manufacturer
3 China Leading Players, Market Share and Ranking
3.1 By Revenue of Lung Disease Therapeutics, China Market Share by Company, 2018-2023
3.2 China Lung Disease Therapeutics Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Industry Chain Analysis
4.1 Lung Disease Therapeutics Industry Chain
4.2 Lung Disease Therapeutics Upstream Analysis
4.2.1 Lung Disease Therapeutics Core Raw Materials
4.2.2 Main Manufacturers of Lung Disease Therapeutics Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Lung Disease Therapeutics Production Mode
4.6 Lung Disease Therapeutics Procurement Model
4.7 Lung Disease Therapeutics Industry Sales Model and Sales Channels
4.7.1 Lung Disease Therapeutics Sales Model
4.7.2 Lung Disease Therapeutics Typical Distributors
5 Sights by Disease Type
5.1 Lung Disease Therapeutics Classification
5.1.1 Asthma
5.1.2 Chronic Obstructive Pulmonary Disease (COPD)
5.1.3 Lung Cancer
5.1.4 Other Lung Diseases
5.2 By Disease Type, Global Lung Disease Therapeutics Consumption Value & CAGR, 2018 VS 2022 VS 2029
5.3 By Disease Type, Global Lung Disease Therapeutics Consumption Value, 2018-2029
6 Sights by Distribution Channel
6.1 Lung Disease Therapeutics Segment by Distribution Channel
6.1.1 Hospital Pharmacies
6.1.2 Retail Pharmacies
6.1.3 Online Pharmacies
6.2 By Distribution Channel, Global Lung Disease Therapeutics Consumption Value & CAGR, 2018 VS 2022 VS 2029
6.3 By Distribution Channel, Global Lung Disease Therapeutics Consumption Value, 2018-2029
7 Sales Sights by Region
7.1 By Region, Global Lung Disease Therapeutics Consumption Value, 2018 VS 2022 VS 2029
7.2 By Region, Global Lung Disease Therapeutics Consumption Value, 2018-2029
7.3 North America
7.3.1 North America Lung Disease Therapeutics & Forecasts, 2018-2029
7.3.2 By Country, North America Lung Disease Therapeutics Market Size Market Share
7.4 Europe
7.4.1 Europe Lung Disease Therapeutics Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Lung Disease Therapeutics Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Lung Disease Therapeutics Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Lung Disease Therapeutics Market Size Market Share
7.6 South America
7.6.1 South America Lung Disease Therapeutics Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Lung Disease Therapeutics Market Size Market Share
7.7 Middle East & Africa
8 Sales Sights by Country Level
8.1 By Country, Global Lung Disease Therapeutics Market Size & CAGR, 2018 VS 2022 VS 2029
8.2 By Country, Global Lung Disease Therapeutics Consumption Value, 2018-2029
8.3 U.S.
8.3.1 U.S. Lung Disease Therapeutics Market Size, 2018-2029
8.3.2 By Disease Type, U.S. Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.3.3 By Distribution Channel, U.S. Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.4 Europe
8.4.1 Europe Lung Disease Therapeutics Market Size, 2018-2029
8.4.2 By Disease Type, Europe Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.4.3 By Distribution Channel, Europe Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.5 China
8.5.1 China Lung Disease Therapeutics Market Size, 2018-2029
8.5.2 By Disease Type, China Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.5.3 By Distribution Channel, China Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.6 Japan
8.6.1 Japan Lung Disease Therapeutics Market Size, 2018-2029
8.6.2 By Disease Type, Japan Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.6.3 By Distribution Channel, Japan Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Lung Disease Therapeutics Market Size, 2018-2029
8.7.2 By Disease Type, South Korea Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.7.3 By Distribution Channel, South Korea Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Lung Disease Therapeutics Market Size, 2018-2029
8.8.2 By Disease Type, Southeast Asia Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.8.3 By Distribution Channel, Southeast Asia Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.9 India
8.9.1 India Lung Disease Therapeutics Market Size, 2018-2029
8.9.2 By Disease Type, India Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.9.3 By Distribution Channel, India Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.10 Middle East & Africa
8.10.1 Middle East & Africa Lung Disease Therapeutics Market Size, 2018-2029
8.10.2 By Disease Type, Middle East & Africa Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
8.10.3 By Distribution Channel, Middle East & Africa Lung Disease Therapeutics Consumption Value Market Share, 2022 VS 2029
9 Company Profile
9.1 GSK
9.1.1 GSK Company Information, Head Office, Market Area and Industry Position
9.1.2 GSK Company Profile and Main Business
9.1.3 GSK Lung Disease Therapeutics Models, Specifications and Application
9.1.4 GSK Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.1.5 GSK Recent Developments
9.2 AstraZeneca
9.2.1 AstraZeneca Company Information, Head Office, Market Area and Industry Position
9.2.2 AstraZeneca Company Profile and Main Business
9.2.3 AstraZeneca Lung Disease Therapeutics Models, Specifications and Application
9.2.4 AstraZeneca Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.2.5 AstraZeneca Recent Developments
9.3 Boehringer Ingelheim
9.3.1 Boehringer Ingelheim Company Information, Head Office, Market Area and Industry Position
9.3.2 Boehringer Ingelheim Company Profile and Main Business
9.3.3 Boehringer Ingelheim Lung Disease Therapeutics Models, Specifications and Application
9.3.4 Boehringer Ingelheim Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.3.5 Boehringer Ingelheim Recent Developments
9.4 Novartis
9.4.1 Novartis Company Information, Head Office, Market Area and Industry Position
9.4.2 Novartis Company Profile and Main Business
9.4.3 Novartis Lung Disease Therapeutics Models, Specifications and Application
9.4.4 Novartis Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.4.5 Novartis Recent Developments
9.5 Mylan
9.5.1 Mylan Company Information, Head Office, Market Area and Industry Position
9.5.2 Mylan Company Profile and Main Business
9.5.3 Mylan Lung Disease Therapeutics Models, Specifications and Application
9.5.4 Mylan Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.5.5 Mylan Recent Developments
9.6 Vertex Pharmaceuticals
9.6.1 Vertex Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
9.6.2 Vertex Pharmaceuticals Company Profile and Main Business
9.6.3 Vertex Pharmaceuticals Lung Disease Therapeutics Models, Specifications and Application
9.6.4 Vertex Pharmaceuticals Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.6.5 Vertex Pharmaceuticals Recent Developments
9.7 F. Hoffman La Roche
9.7.1 F. Hoffman La Roche Company Information, Head Office, Market Area and Industry Position
9.7.2 F. Hoffman La Roche Company Profile and Main Business
9.7.3 F. Hoffman La Roche Lung Disease Therapeutics Models, Specifications and Application
9.7.4 F. Hoffman La Roche Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.7.5 F. Hoffman La Roche Recent Developments
9.8 Teva Pharmaceuticals
9.8.1 Teva Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
9.8.2 Teva Pharmaceuticals Company Profile and Main Business
9.8.3 Teva Pharmaceuticals Lung Disease Therapeutics Models, Specifications and Application
9.8.4 Teva Pharmaceuticals Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.8.5 Teva Pharmaceuticals Recent Developments
9.9 Cipla
9.9.1 Cipla Company Information, Head Office, Market Area and Industry Position
9.9.2 Cipla Company Profile and Main Business
9.9.3 Cipla Lung Disease Therapeutics Models, Specifications and Application
9.9.4 Cipla Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.9.5 Cipla Recent Developments
9.10 Fibrogen
9.10.1 Fibrogen Company Information, Head Office, Market Area and Industry Position
9.10.2 Fibrogen Company Profile and Main Business
9.10.3 Fibrogen Lung Disease Therapeutics Models, Specifications and Application
9.10.4 Fibrogen Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.10.5 Fibrogen Recent Developments
9.11 Liminal Biosciences
9.11.1 Liminal Biosciences Company Information, Head Office, Market Area and Industry Position
9.11.2 Liminal Biosciences Company Profile and Main Business
9.11.3 Liminal Biosciences Lung Disease Therapeutics Models, Specifications and Application
9.11.4 Liminal Biosciences Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.11.5 Liminal Biosciences Recent Developments
9.12 PharmAkea Therapeutics
9.12.1 PharmAkea Therapeutics Company Information, Head Office, Market Area and Industry Position
9.12.2 PharmAkea Therapeutics Company Profile and Main Business
9.12.3 PharmAkea Therapeutics Lung Disease Therapeutics Models, Specifications and Application
9.12.4 PharmAkea Therapeutics Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.12.5 PharmAkea Therapeutics Recent Developments
9.13 IQVIA
9.13.1 IQVIA Company Information, Head Office, Market Area and Industry Position
9.13.2 IQVIA Company Profile and Main Business
9.13.3 IQVIA Lung Disease Therapeutics Models, Specifications and Application
9.13.4 IQVIA Lung Disease Therapeutics Revenue and Gross Margin, 2018-2023
9.13.5 IQVIA Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
Historical Data (2015-2019) |
|
|
Influencing Factors |
|
|
Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
Market Size |
|
|
Market Position of Top Company |
|
|
Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
Primary Sources | Parameters | Key Data |
Market Segments(by Application, by Type) |
|
|
Total Market |
|
|